335280-19-8

Basic information

• Product Name: N-Boc-trans-3-hydroxy-D-proline
• Synonyms: N-Boc-trans-3-hydroxy-D-proline;(2R,3R)-3-Hydroxy-1,2-pyrrolidinedicarboxylic acid 1-(1,1-dimethylethyl) ester;(2R,3R)-1-(tert-Butoxycarbonyl)-3-hydroxypyrrolidine-2-carboxylic acid;Boc-trans-3-Hydroxy-D-proline
• CAS NO: 335280-19-8
• Molecular Formula: C10H17NO5
• Molecular Weight: 231.24568
• Mol File: 335280-19-8.mol
• Article Data: 40

Chemical Properties

• Boiling Point: 390.9±42.0 °C(Predicted)
• Appearance: /
• Density: 1.312±0.06 g/cm3 (20 ºC 760 Torr)
• PKA: 3.69±0.40(Predicted)
• CAS DataBase Reference: N-Boc-trans-3-hydroxy-D-proline(CAS DataBase Reference)
• NIST Chemistry Reference: N-Boc-trans-3-hydroxy-D-proline(335280-19-8)
• EPA Substance Registry System: N-Boc-trans-3-hydroxy-D-proline(335280-19-8)

Safety Data

• Hazardous Substances Data: 335280-19-8(Hazardous Substances Data)

Usage

General Description

N-Boc-trans-3-hydroxy-D-proline, also known as N-Boc-3-hydroxy-D-proline, is a chemical compound commonly used in organic synthesis. It is a derivative of proline, an amino acid that is found in proteins. The N-Boc (tert-butoxycarbonyl) group is a protecting group used to temporarily block the reactivity of the amine group in proline, allowing for selective reactions at other functional groups. The trans-3-hydroxy-D configuration indicates the specific stereochemistry of the compound, which is important in its reactivity and biological activity. N-Boc-trans-3-hydroxy-D-proline is often used as a building block in the synthesis of pharmaceuticals, peptides, and other organic compounds due to its unique structure and reactivity.

Upstream product

• 118492-88-9 cis-3-acetoxy-N-(tert-butoxycarbonyl)-D-proline 
• 24424-99-5 di-tert-butyl dicarbonate 
• 361367-98-8 N-tert-butoxycarbonyl-cis-3-(p-nitrobenzoyloxy)-L-proline methyl ester 
• 187039-57-2 (2S,3S)-1-(tert-butoxycarbonyl)-3-hydroxypyrrolidine-2-carboxylic acid 
• 4298-08-2 trans-3-hydroxy-L-proline 
• 104069-26-3 cis-3-hydroxy-D-proline 
• 184046-78-4 (2S,3S)-1-tert-butyl-2-methyl 3-hydroxypyrrolidine-1,2-dicarboxylate 
• 34619-03-9 tert-butyldicarbonate 
• 7087-68-5 N-ethyl-N,N-diisopropylamine 
• 14916-76-8 trans-3-Hydroxy-(L)-proline 
• 567-36-2 3-hydroxypyrrolidine-2-carboxylic acid 
• 58632-95-4 2-(tert-Butoxycarbonyloxyimino)-2-phenylacetonitrile 
• 119677-21-3 (2R,3R)-3-hydroxypyrrolidine-2-carboxylic acid 
• 174389-15-2 (2S,3R)-3-(tert-Butyl-diphenyl-silanyloxy)-2-hydroxymethyl-pyrrolidine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 184046-78-4 (2S,3S)-1-tert-butyl-2-methyl 3-hydroxypyrrolidine-1,2-dicarboxylate 
• 186132-96-7 (2S,3R)-1-[(tert-butoxy)carbonyl]-3-hydroxypyrrolidine-2-carboxylic acid 
• 330945-11-4 2-benzyl 1-(tert-butyl) (2R,3R)-3-fluoropyrrolidine-1,2-dicarboxylate 
• 370880-27-6 2,6-diazabicylo[3.2.0]heptane-2-carboxylic acid tert-butyl ester 
• 2165699-77-2 (2S,3R)-1-(tert-butoxycarbonyl)-3-methoxypyrrolidine-2-carboxylic acid 

Relevant articles and documents

PCSK9 ANTAGONIST COMPOUNDS

Disclosed are compounds of Formula (I), or a pharmaceutically acceptable salt thereof: (I) wherein A, A1, A2, R1, R2 and R3 are as defined herein, which compounds have properties for antagonizing PCSK9. Also described are pharmaceutical formulations comprising the compounds of Formula I or their salts, and methods of treating cardiovascular disease and conditions related to PCSK9 activity, e.g. atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions.

PYRROLIDINE OREXIN RECEPTOR AGONISTS

The present invention is directed to pyrrolidine compounds which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.

SULFONAMIDE COMPOUNDS HAVING TNAP INHIBITORY ACTIVITY

The present invention relates to a compound or a pharmacologically acceptable salt thereof having excellent tissue non-specific alkaline phosphatase inhibitory activity. The present invention provides a compound represented by the formula (I) or a pharmacologically acceptable salt thereof.